Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis

George Goucher, MD; Fred Saad, MD; Himu Lukka, MD; Anil Kapoor, MD

1Department of Surgery (Urology) and Oncology, McMaster University, Hamilton, ON, Canada; 2Department of GU Oncology, l’Université de Montréal, Montreal, QC, Canada; 3Department of Radiation Oncology, McMaster University, Hamilton, ON, Canada

Background

Hemorrhagic cystitis refers to a collection of symptoms and signs defined by hematuria, lower urinary tract symptoms (LUTS), and cystoscopic findings indicative of underlying urothelial damage. It can have a number underlying causative factors: treatment with chemotherapeutic agents (such as cyclophosphamide and concurrent therapies); post-transplant patients; infection-mediated; treatment with radiation therapy. RHC is often an adverse event in patients with previous radiation to the pelvis for urological or gynecological malignancy and will be the focus of this BPR.

RHC is generally considered a separate pathological process from acute radiation effects, with early signs of urothelial effects occurring at three months and pathological changes occurring 6–12 months after radiation.1 New-onset symptoms have been recorded up to 20 years after radiation treatment.4 The estimates for prevalence of RHC after radiation treatment varies widely depending on the diagnostic definitions used, but different studies have quoted them as 9–21% following treatment of prostate cancer, 3–6.7% for cervical cancer, and 2–47% for bladder cancer.3 The use of modern treatment techniques, such as intensity-modulated radiation therapy and volumetric modulated arc therapy, have reduced the radiation dose to the bladder. Randomized studies have shown that the use of higher doses in the management of prostate cancer have resulted improved prostate-specific antigen (PSA) control using these modern treatment techniques, but with the same incidence of late complications. There has also been a trend to using hypofractionation radiotherapy regimens (higher dose per fraction given over a shorter timeframe). To minimize late bladder effects, emphasis needs to be paid to ensuring doses received by radiovulnerable structures, such as bowel and bladder, are kept within acceptable limits.

The exact mechanism by which radiation causes damage to the bladder is not entirely understood, but believed to be multifactorial. While direct damage to DNA is believed to be...
rare, it is hypothesized that indirect damage occurs through the creation of free radicals. Histological studies have demonstrated increased proliferation of the urothelium in the months following radiation. Damage to tight cellular junctions and the loss of the normal polysaccharide layer allow for increased permeability of urine bacteria and metabolites causing increased damage to the underlying tissue. This altered permeability of the urothelial cell layer has been demonstrated to be involved in late-stage radiation changes in rat models and is hypothesized to play a large role in the development of post-radiation urinary symptoms.

Diffuse mucosal edema is noted in biopsies taken immediately post-radiation. This is followed by development of vascular telangiectasia, submucosal hemorrhage, and interstitial fibrosis. Subendothelial proliferation, edema, and medial thickening may progressively deplete the blood supply to urothelium, resulting in endarteritis obliterans causing acute and chronic ischemia. These ischemic and necrotic changes are proposed to give rise to subsequent development of revascularization with superficial, fragile vessels that are responsible for bleeding in radiation cystitis.

Hospitalizations for RHC can be lengthy and costly. A recent retrospective study assessing 1111 patients admitted for RHC in 2013 showed the median cost associated with each admission to be $7157 USD. This number rose to $11 100 for those with hematuria severe enough to merit endoscopic evaluation/treatment. Multiple studies have demonstrated the significant effect its protracted and recurrent nature can have on patient-rated quality of life scales. There exists little consensus of how to best treat RHC, and previous surveys of practicing urologist have shown a lack of awareness of treatment options available.

Classifications

The European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group (EORTC/RTOG) classification of late radiation effects is a commonly used classification system for grading of RHC (Table 1). It describes a combination of clinical and cystoscopic criteria for reporting late radiation effects. The Late Effects of Normal Tissues (LEBT)/SOMA scale has also been developed and uses a more complex combination of subjective, objective, management, and analytical factors into radiation effect classification. A more recent move to replace these systems with a common terminology has led to the development of the Common Terminology Criteria for Adverse Events as a uniform lexicon for description of cancer-related adverse effects.

Initial management

Diagnosis and early assessment

In patients presenting with hematuria post-radiation, a thorough assessment is needed to rule out secondary causes before a diagnosis of RHC can be made. In a study exploring cystoscopic evaluation of 185 men treated with brachytherapy for prostate cancer who presented with either macroscopic hematuria, microscopic hematuria, or persistent lower urinary tract, 9.6% were found to have a new bladder tumor compared to 7% who were found to have radiation cystitis. While the majority of these symptomatic post-brachytherapy patients had cystoscopies reported as normal (63.8%), a clinically significant number did have an observable etiology. Assessment should begin with a detailed history characterizing the symptoms and confirming the history and treatment plan of a patient’s radiation therapy. Physical exams, including an abdominal and pelvic exam to assess for alternative causes of bleeding, should be included. Laboratory tests, including a complete blood count, coagulation studies, serum creatinine, urinalyses, urine culture and cytology, should be initiated. As with any patient presenting with hematuria and a high risk of malignancy, all patients should undergo axial imaging, preferably a computed tomography (CT)-urogram to assess for upper tract sources of bleeding, and should also undergo cystoscopic evaluation and biopsies of lesions concerning for malignancy. Mild symptoms may resolve with continuous bladder irrigation with saline solution and this should be tried first in all patients with hematuria associated with clotting or retention.

Recommendation: Assessment of a patient complaining of hematuria post-radiation therapy should identify or exclude other pathological factors that may explain or contribute to the patient’s symptoms (Grade 4C).

Cystoscopic evaluation

Cystoscopy in patients with new-onset or suspected RHC can be both diagnostic and therapeutic. The appearance of
diffuse erythema, telangiectasia with or without ulcerations can help confirm the diagnosis of RHC. At the time of cystoscopy, fulguration of suspected vascular lesions may provide control of hematuria. A case series assessing the effectiveness of cystoscopy and fulguration for hematuria control in patients with either radiation- or chemotherapy-induced symptoms, 61% (20/33) of patients achieved resolution of symptoms after initial endoscopic treatment. Only 36% (4/11) of patients who had refractory symptoms responded to a second cystoscopy and fulguration.

Multiple small case series have assessed alternatives to fulguration with Greenlight laser, KTP laser treatment, and argon beam coagulator. All series report laser therapy being well-tolerated and having a beneficial effect. In the future, they may play a larger role in the treatment of RHC; however, until larger studies can confirm their safety and effectiveness, they remain experimental in nature. Additional studies have investigated intravesical hemostatic gelatin matrix (Floseal) in six patients and was noted to be beneficial. Fibrin glue has been trialed in the treatment of post-hematological stem cell transplant patients and found to reduce hematuria, but it has yet to be investigated in the RHC population beyond individual case studies.

**Recommendation:** All patients with hematuria should undergo at least one initial cystoscopy with or without fulguration of suspect lesions and biopsy of any lesions concerning for malignancy for diagnostic and therapeutic purposes (Grade 3C). Laser therapy and endoscopic use of hemostatic agents may play a role in early management of RHC, but insufficient data exists to evaluate their efficacy and safety; long-term followup is needed prior to any recommendations being made (Grade 3D).

---

**Persistent or recurrent clinically significant hematuria**

**Intravesical agents**

**Alum irrigation**

Intravesical aluminous salts act as an astringent agent and exert their effect through protein precipitation causing decreased capillary permeability, contraction of intercellular space, vasoconstriction, and hardening of the capillary endothelium. It is typically administered as a 1% concentration of alum mixed with sterile water, irrigated through the bladder at 250–300 ml per hour, at a duration up to the discretion of the observing clinician. Ideally, the bladder should be irrigated free of clots prior to initiation of therapy. Historical case series have demonstrated the efficacy and tolerability of intravesical alum for a wide range of etiologies and presentations of intractable bladder hemorrhages. The common side effects are bladder spasms, suprapubic discomfort, and clotting of the catheter due to precipitant formation. Individual case studies have reported a risk of aluminum toxicity in individuals in renal failure.

The most recent, and largest case series reported the use of alum irrigation in 40 patients (38 of whom had previous radiation treatment) with symptoms of hemorrhagic cystitis; 60% of these patients demonstrated an improvement in their symptoms and required no further treatment prior to discharge. The treatment was well-tolerated and 90% of patients were able to receive their treatment as prescribed. Two patients discontinued due to inability to tolerate bladder spasms and two for altered level of consciousness. Overall, 35% of patients experienced bladder spasms. Asymptomatic elevation in serum aluminum was detected in one patient that resolved on discontinuation of the treatment. At a median followup of 16.5 months, only 32% of patients required no further treatment, bringing the durability of this treatment into question.

**Recommendation:** Irrigation with alum is a practical and easily applied treatment for RHC with a comparatively acute onset of action that is generally well-tolerated. Special caution should be used in patients with poor renal function (Grade 3C).

**Hyaluronic acid**

Hyaluronic acid (HA) is a mucopolysaccharide whose therapeutic benefit is believed to be mediated by the repair of the normal glycoaminoglycan layer of the bladder when applied as intravesical installations. It has been shown that radiation leads to defects in this protective layer, leading to chronic inflammatory changes and delayed or prevented healing of urothelial cells. Its use as an intravesical agent is well-studied in the treatment of interstitial cystitis and painful bladder syndrome, where it was recently recommended as a treatment option in the Canadian Urological Association guideline.

One of the few randomized trials comparing treatment modalities for RHC randomized 36 patients to either intravesical therapy with HA or treatment with hyperbaric oxygen therapy (HBOT). In the HA group, patients received intravesical therapy once weekly for two months and then monthly for two months. Patients in the HBOT group received daily treatments for 30 treatments. Followup assessment of symptoms were done at six, 12, and 18 months following therapy. Complete resolution of hematuria was noted in 88%, 75%, and 50% of HA patients at those intervals and in 75%, 50%, and 45% of patients in the HBOT group. The difference was not statistically significant at any interval and the author concluded the HA therapy was at least as effective as HBOT in the treatment of hematuria.

A prospective, observational study of 20 patients undergoing treatment with intravesical HA compared grading of radiation cystitis, including hematuria, as per EORTC/ROTG classification (scale 1–5) before treatment and again three months
and bother. In a study published by Gacci et al, the mean radiocystitis scores before and after HA treatment were 2.70 and 1.45, respectively (p<0.01), with only minor side effects described. It is notable that no patients with grade 4 or 5 toxicity, considered severe symptoms, were included in this study. Beyond hematuria, recent prospectively collected data suggests that intravesical treatment with HA in combination with chondroitin sulfate (another glycosaminoglycan) produces a clinically significant improvement in post-radiation LUTS and bother. In a study published by Gacci et al, 80 patients with previous radiation therapy and new-onset or worsening LUTS symptoms were shown to have a statistically significant reduction in urgency, frequency, nocturia, and bladder pain, as measured by patient-reported outcomes after intravesical treatment with HA and chondroitin sulfate.

Recommendation: Intravesical therapy with HA may improve symptoms of RHC and may provide further benefit in those with significant LUTS. Its slow onset of action and lack of research in severe hematuria may limit its usefulness in the acute or inpatient setting (Grade 3C).

Other intravesical agents

Intravesical instillation of the antifibrinolytic agent epsilon aminocaproic acid (EACA) was shown to improve hematuria in 34 patients in case series of 37 patients with intractable bladder hemorrhage, most of whom had either radiation- or cyclophosphamide-induced cystitis; however this has not been repeated in contemporary studies since its publication in 1992. Intravesical instillations of prostaglandins have been demonstrated in several smaller case series to be effective in treating hemorrhagic cystitis secondary to treatment with cyclophosphamide, but there are no large studies to suggest their effectiveness in RHC. Silver nitrate instillations have been tried and were found to be ineffective in limiting RHC.

Recommendation: Several intravesical options have been trialed in limited case series, but require replication, etiology-specific assessment, or comparative data before they can be formally included as recommendations (Grade 3D).

Systemic agents

Hyperbaric oxygen therapy (HBOT)

Radiation to the bladder causes oblitative endarteritis of blood vessels creating cellular hypoxia, bladder ischemia, and fibrosis. This may lead to superficial fragile blood vessels prone to recurrent bleeding. Patients who undergo HBOT inhale 100% O₂ at pressures of 1.4–3.0 ATM, allowing for hyperoxegenation of tissue. Hyperoxia induces primary neovascularization, secondary growth of healthy granulation tissue, and induces short-term vasoconstriction that may help control active bleeding.

HBOT is the most studied treatment option for RHC. A scoping review and meta-analyses evaluating this treatment on resolution of hematuria was recently published. It included one small, randomized control trial, two prospective trials, and 11 retrospective case series. This meta-analysis represents 602 patients followed for at least one year. Partial or complete response was noted in 84% of patients (confidence interval [CI] 76–91) in the pooled analysis. The most common complications were barotrauma, frequent barotraumatic otitis in 6% of participants. Visual field disturbances were noted in 1% of participants.

Select case series offer followup data available for up to a decade after treatment and seem to suggest that successful treatment with HBOT may offer a durable response for patients. One study followed 32 of its participants for an average of 11.6 years and found the resolution rate of macroscopic hematuria to be 81%. A smaller case series supported this data, as 12 of 13 participants remained free of hematuria at 10 years. Recently, authors have sought to describe their experience using HBOT as a primary therapy in cases of severe RHC. In one study, 38 patients presenting with grade IV EORTC hematuria requiring transfusions received HBOT therapy as first-line monotherapy. After an average of 33 treatments, 87% of patients had complete resolution of hematuria. Long-term data were not available to assess the durability to of treatment.

Recommendation: Multiple studies have demonstrated that HBOT is safe and effective and should be considered an early treatment option for RHC in patients who have failed cystoscopy and fulguration. Due to significant resource and expertise requirements, its use may be limited based on access and availability (Grade 3C).

Sodium pentosan polysulfate

Sodium pentosan polysulfate (SPP) is a semisynthetic polysaccharide formulated as an oral medication that serves as a synthetic glycosaminoglycan. It adheres to the bladder mucosa, where it supplements the bladder’s own glycosaminoglycan layer in a similar fashion as intravesical treatment with HA. It has been previously shown to be effective in the treatment of interstitial cystitis. The largest study to assess its effectiveness in hematuria secondary to radiation followed 60 consecutively enrolled patients who were treated with 100 mg orally of SPP three times daily. In 10 patients, hematuria was noted to have resolved completely, and there was partial resolution in 21 patients. However, the applicability of this study was limited by the large number of participants not available for followup or who passed away during the study from causes unrelated to hematuria. Two other small case series have also demonstrated the benefits of oral SPP. Its usefulness was noted primarily by its safety, tolerability, and ease of administration; however, the onset of action was found to be 1–8 weeks, limiting its use in the acute setting. A recent case series has suggested a risk of pigmentary maculopathy associated with long-term chronic use of SPP (median duration of 186 months).
Recommendation: Several case series have shown a potential reduction of hematuria with treatment with SPP in patients with RHC. It is safe and generally well-tolerated, however, the slow onset of action may limit its usefulness in treatment of acute or severe RHC (Grade 3C).

Experimental options

WF10, an intravenously administered macrophage regulator, has shown promising results for treatment and decreased recurrence of RCH in two studies published at a single centre, but is not commercially available in Canada.50 A randomized control trial recently published in 2018 included 45,46 patients undergoing pelvic radiation; however, there is no data to suggest it has a role in management of late-effect RHC.57-59

There is conflicting evidence that may point to a role for cranberry juice in preventing acute urinary symptoms in patients undergoing pelvic radiation; however, there is no data to suggest it has a role in management of late-effect RHC.57-59

There is a growing body of evidence exploring the use of tranexamic acid in the control of hemorrhage of multiple etiologies. Its use has previously been suggested in the management of RHC. A randomized control trial recently assessed the use of intravenous tranexamic acid in controlling of hematuria of multiple etiologies in the acute setting. It found a decreased time on CBI until resolution of hematuria; however, no significant difference in blood loss or transfusion rates were noticed in the treatment group. While further studies may demonstrate a benefit in treatment of patients with RHC with tranexamic acid, at this time there is insufficient published data to support this.

Recommendation: Multiple systemic agents have been used in small experimental situations for treatment of RHC. Until further studies are completed, no formal recommendations can be made regarding their use (Grade 3D).

Refractory and life-threatening hematuria

Transarterial embolization

Advances in interventional radiology have allowed for accurate selective and super-selective transarterial embolizations (TAE) that provide clinicians with management alternatives to more radical surgical procedures in patients with persistent or life-threatening hematuria. The benefit of TAE is its safety and tolerability in comparison to more aggressive surgical procedures in the frail and elderly patients, who make up a significant proportion of patients with RHC. However, these procedures are not without their own risks and side effects.

Unfortunately, many of the studies on TAE for hematuria include urological bleeding of multiple etiologies and do not discriminate between blood loss from bladder or prostatic origins. In a case series of 44 patients looking at the role of TAE in the management of intractable hematuria hemorrhage of oncological origin, Liguri et al found that the majority of patients (82%) experienced an initial resolution of hematuria. The ability to perform selective and super-selective TAE has reduced the risk of ischemic-related side effects. Historical studies have demonstrated ischemic-mediated side effects in as high as 65% in patients undergoing internal iliac artery embolization. Although most of these are transient post-embolization syndrome, they also include more serious complications, such as bladder necrosis and, in rare cases, Brown-Sequard syndrome. Comparable modern series published in the last decade quote minor and self-resolving complication rates from 9–31%, with a technical success rate of 88–100%.

Recommendation: TAE is a viable option for control of RHC in those for whom less invasive methods have been unsuccessful. Preference should be given to selective or super-selective embolization when available to lessen possible side effects (Grade 3C).

Formalin

Intravesical formalin was first described in the treatment of bladder hemorrhage in the late 1960s, and was soon assessed in a RHC cohort. The proposed mechanism involved capillary occlusion and protein fixation at the urothelium level. Due to pain with administration, it must administered in an operating room setting with either a general or spinal anesthetic. While its rapid onset of action is appealing, its use is somewhat controversial because of its high morbidity, which appears to be proportional to the concentration of formalin used.

The largest review of the efficacy of formalin instillation to treat hemorrhagic cystitis of multiple etiologies was a systematic review of retrospective case series published in 1989. The article included 235 patients stratified into three groups by the concentration of formalin instilled (10% vs. 3–6% vs. 1–2%). The complete response rates were 88%, 78%, and 71%, respectively. One benefit of formalin instillations was that complete response was typically achieved within 48 hours of a single instillation. Major complications were typically associated with refluxing into the upper urinary tract and consisted of ureteric stricture function, ureteropelvic junction and ureterovesical junction obstruction requiring urinary diversion, decreased bladder capacity, and vesicourethral fistulas. The mortality rates for 10% and 4–6% formalin instillation were recorded at 5.7% and 2.2%, respectively. No mortalities occurred in the 21 patients treated with 1–2% concentration.

Several other studies were completed that found formalin to be associated with a high treatment efficacy, but with
potentially severe complications. In a study of 35 patient with RHC post-cervical radiation, 89% were found to have complete response after a single instillations; however, 31% had major complications.\textsuperscript{58} One contemporary study investigated eight patients treated with formalin instillations after less invasive treatments had failed. In this study, each patient had a preoperative cystogram to assess for perforation or vesicoureteral reflux, and if any reflux was suspected, Fogarty catheters were used to obstruct the ureter.\textsuperscript{56} Formalin concentration ranged from 1–4% and contact time was kept to 10–15 minutes. The complete resolution rate was 75% and only one patient had major complications necessitating intensive care unit admission. A detailed description of the procedure can be found within this article for clinicians unfamiliar with this treatment option.

Procedural variations for decreasing the morbidity associated with formalin instillations have been proposed, from decreasing formalin concentration to alternative methods of formalin delivery. A small, prospective study compared intravesical instillation of 4% formalin in 11 patients to endoscopic placement of formalin soaked pledgets.\textsuperscript{59} Success rate was similar (82% and 75%, respectively), however the intravesicle instillation group suffered from four major complications, whereas the pledget group suffered only minor side effects. The differences were not statistically significant and while a comparable method was described in two individual case studies,\textsuperscript{60,61} followup with further larger or prospective studies is lacking.

**Recommendation: Due to significant morbidity associated with the procedure, formalin instillations should only be used in those who have failed less invasive treatments. If treatment is necessary, all attempts should be made to prevent reflux into the upper tracts, and the patient needs careful monitoring for potential side effects (Grade 3C).**

**Cystectomy and urinary diversion**

Unfortunately, a small percentage of patients will present with life-threatening hemorrhagic cystitis that is refractory to conservative and non-operative measures. These patients can be successfully treated with urinary diversion and cystectomy, however, the associated morbidity with this procedure is high. Several case series have examined the use of cystectomy in patients who had previously failed less invasive therapies. One series identified 21 patients with hemorrhagic cystitis, 17 from radiation therapy, who underwent cystectomy.\textsuperscript{62} In this series, 42% of patients experienced severe complications (defined as Clavien grade III–V) and the 90-day mortality rate was 16%. This study echoes the findings of a larger case series looking at surgical outcomes from men undergoing urinary diversion via cystectomy for multiple adverse effects of radiation, including hematuria.\textsuperscript{63} In this series, 36% of patients experienced Clavian III or greater complications, including 15% who required a second operation, and death in 4.5% of patients within the first 90 days. These rates of complications outpace the comparable rates in patients undergoing radical cystectomy for bladder cancer. Both authors attributed this to baseline fragility and comorbidities in this patient population exacerbated with the challenge of operating in a previously radiated field.

Small case studies have evaluated the use of urinary diversion alone in those who may not tolerate a cystectomy, either through cutaneous ureterostomy\textsuperscript{64} or bilateral nephrostomy tubes.\textsuperscript{65} Although both studies were quite small, they showed improvement in hematuria using urinary diversion alone; this may be a beneficial surgical alternative in patients for whom cystectomy is not a viable option. Caution should be advised, as long-term followup in urinary diversion without cystectomy for benign conditions has shown a high rate of complications in the remaining bladder.\textsuperscript{56}

**Recommendation: Urinary diversion with or without cystectomy for RHC should be reserved only for those who have failed previously available therapy, and clinicians and patients should be aware of the high morbidity and mortality of the procedure before proceeding with surgery (Grade 3C).**

**Discussion**

**Treatment sequencing**

There is a lack of consensus or comparative evidence to suggest superiority of one treatment of RHC over another. The lack of high-quality evidence has limited the ability for previous authors to conclusively state the order that treatment should be provided in the cases of refractory therapy. There have been several previous attempts to make recommendations for treatment algorithms, with the general consensus that treatments should be offered initially using the least invasive approaches and progressing to more invasive approaches as a general principle.\textsuperscript{67-71}

This report seeks to provide a logical and stepwise approach to the management of radiation cystitis. Given the wide variety of clinical states that a patient with RHC may present, a linear treatment algorithm would be insufficient to provide treatment suggestions appropriate for different patients depending on the acuity and severity of the symptoms. Instead we have divided our treatments into three groups based on severity of clinical presentation and associated morbidity with treatment options (Fig. 1). The first box represents initial management and provides suggestions for investigations and supportive therapy. It is focused on upfront investigations to rule out other causes that may explain or exacerbate hemorrhagic cystitis. Underlying cor-
**Fig. 1.** Treatment recommendations. CT Uro: computed tomography urogram; HA: hyaluronic acid; HBOT: hyperbaric oxygen therapy; LUTS: lower urinary tract symptom; SPP: sodium pentosan polysulfate; tx: treatment.

RHC remains a challenging medical condition that often presents in a frail and vulnerable population. In this report, we have presented a general approach and suggestions for management, as well as an overview of key research supporting specific therapies. These guidelines should always be used in the context of an individual patient’s presentation, and may continue to evolve, as more evidence becomes available on the subject.

**Competing interests:** Dr. Saad reports personal fees and research grants from Amgen Inc, Astellas, Bayer, Janssen, and Sanofi. Dr. Lukka is a speaker for Astellas; has received grants and/or honoraria from Abbvie, Actavis, Amgen, Astellas; Bayer, Ferring, Janssen, Sanofi, and Tensco; owns stock and options in Vertex Pharmaceutical; and has participated in clinical trials supported by Bayer and Janssen. Dr. Kapoor has been an advisor for and has participated in clinical trials supported by Amgen, Astellas, GSK, Janssen, Novartis, Pfizer, and Sanofi. The remaining authors report no competing personal or financial interest related to this work.

This paper has been peer-reviewed.

**References**

BPR: Radiation-induced hemorrhagic cystitis